study

In the middle of the twentieth century, doctors explored hormone treatments for various conditions linked to aging. One area of interest was senile pruritus and senile eczema, terms used at the time for intense itching and skin inflammation that often affected older people. Researchers noticed that these problems sometimes appeared alongside declining hormone levels, particularly in men. This led to small experiments with testosterone as a possible remedy.

A notable report came in 1945 from doctors William L. Dobes, Jack Jones, and Andrew G. Franks at Emory University. They published their findings in The Journal of Clinical Endocrinology & Metabolism. The team worked with ten patients who had senile pruritus, a condition marked by severe, widespread itching and sometimes skin changes resembling eczema. The patients received testosterone propionate through injections, local skin applications, and oral methyl testosterone.

According to the doctors, the treatment brought noticeable relief for many in the group. Itching decreased and skin symptoms improved in a good number of cases, especially when the issues seemed tied to age-related hormone decline. One example mentioned involved a patient whose pruritus and dermatitis came under control with testosterone after vitamins had not helped. The results were presented as promising for this specific type of age-related skin complaint.

These early observations fit with the idea that testosterone can influence the immune system. Modern understanding shows that testosterone tends to suppress Th2 immune responses, the type often overactive in atopic eczema and allergic skin conditions. By calming this pathway, the hormone could in theory reduce inflammation and itching. However, the 1940s work was not a large or tightly controlled clinical trial by today's standards. It involved only a handful of patients, lacked placebo comparisons, and focused mainly on older adults with senile forms of skin trouble rather than common atopic eczema seen in children or younger adults.

Later medical research has not turned testosterone into a standard treatment for eczema. Some studies have looked at hormone levels in people with atopic dermatitis and explored how testosterone might affect skin barrier function or inflammation, but results remain mixed. While it may help certain inflammatory aspects, there are also concerns that androgens can sometimes affect skin thickness or oil production in ways that are not always beneficial. No large-scale modern trials have established testosterone as a safe or effective option for routine eczema care.

The historical use of testosterone for senile pruritus and eczema reflects an era when doctors were just beginning to connect hormones with skin health and aging. Those small studies from the 1940s reported positive outcomes in relieving symptoms for many participants, yet they stayed limited in scope. Today, eczema management relies on moisturizers, topical steroids, newer anti-inflammatory creams, and other targeted therapies. The old experiments with testosterone serve mainly as an interesting footnote in medical history, highlighting how hormone balance can play a role in skin conditions.

(Source : Grok)

Cordyceps, also known as Cordyceps sinensis or Ophiocordyceps sinensis, is a fungus that has been used for centuries in traditional Chinese medicine to support respiratory health, boost energy, and ease breathing difficulties. Modern research has examined whether it can help people with lung conditions such as chronic obstructive pulmonary disease, chronic bronchitis, and asthma, mainly by reducing inflammation and oxidative stress in the airways.

Several human studies provide evidence for these potential benefits. A systematic review and meta-analysis published in 2019 looked at fifteen clinical trials involving 1,238 adults with stable chronic obstructive pulmonary disease at GOLD stages 2 or 3. When Cordyceps preparations or formulas were added to standard care, patients showed improvements in lung function measures such as the ratio of forced expiratory volume in one second to forced vital capacity, better exercise endurance, higher quality of life scores, and fewer symptoms compared with standard care alone. Another randomized, double-blind, placebo-controlled trial in 2024 tested Bailing capsules, a preparation made from Cordyceps sinensis mycelium, in 240 adults with chronic bronchitis. Participants took 2 grams of the capsule three times daily for forty-eight weeks or received a placebo. Those in the Cordyceps group experienced significantly fewer acute exacerbations of chronic bronchitis during both the treatment period and a follow-up phase. They also reported milder symptoms of expectoration and wheezing, although direct measurements of lung function such as forced expiratory volume did not differ markedly between groups. In a separate randomized study from 2016, 120 adults with moderate-to-severe persistent asthma received either standard inhaled corticosteroids and long-acting beta-agonists alone or the same therapy plus Corbrin capsules containing 1.2 grams of Cordyceps sinensis three times daily for three months. The group taking Cordyceps showed better asthma control, improved lung function, reduced inflammation markers, and higher quality-of-life scores.

Animal research helps explain how Cordyceps might protect the lungs. In mice with bleomycin-induced idiopathic pulmonary fibrosis, Cordyceps treatment reduced lung inflammation and collagen buildup. In rat models of chronic obstructive pulmonary disease, it lowered levels of inflammatory cells in the airways, decreased certain cytokines in the blood, and improved the ratio of forced expiratory volume to forced vital capacity. These effects appear consistent across several rodent studies.

The main active compounds responsible for these lung-supporting actions are cordycepin, a nucleoside similar to adenosine, and various polysaccharides. Cordycepin works by blocking key inflammatory pathways inside cells, particularly the NF-κB route and the TLR4/MyD88 signaling that triggers the release of pro-inflammatory molecules such as tumor necrosis factor alpha, interleukin-6, and inducible nitric oxide synthase. This reduces swelling and tissue damage in the airways. The polysaccharides also calm inflammation and support immune balance while helping to lower oxidative stress by decreasing harmful reactive oxygen species produced by damaged mitochondria in lung cells. Together these molecules improve oxygen uptake, ease airway constriction, and protect lung tissue from further harm caused by chronic inflammation or environmental irritants.

Cordyceps is generally considered safe for most healthy adults when taken at typical doses of 3 to 6 grams per day for up to one year, with only mild side effects such as occasional stomach discomfort reported in trials. However, the evidence is stronger for use as an add-on therapy alongside conventional treatments rather than as a replacement. Most positive results come from studies on people with stable, moderate lung conditions, and larger, longer-term trials are still needed to confirm benefits for healthy lungs or more severe disease. Anyone with a serious respiratory condition should consult a doctor before adding Cordyceps, especially if they have weakened immunity or are taking medications that affect the immune system.

In summary, Cordyceps shows promise as a supportive option for lung health, particularly in helping to reduce flare-ups, ease breathing symptoms, and modestly improve function in people with chronic bronchitis, chronic obstructive pulmonary disease, or asthma. Its effects stem largely from the anti-inflammatory and antioxidant actions of cordycepin and polysaccharides, which target the underlying processes that damage lung tissue over time. While not a cure, it offers a complementary approach backed by a growing body of clinical and laboratory data.

(Source : Grok)

Reishi mushroom, known scientifically as Ganoderma lucidum, is a woody fungus with a shiny, reddish-brown cap that has been prized in traditional Chinese and Japanese medicine for centuries as a tonic to strengthen the body’s defenses. Today researchers focus on its possible effects on the immune system, the complex network of cells, organs, and signaling molecules that protects against infection and abnormal cell growth. The question many people ask is whether reishi actually helps the immune system work better, how it might do so at a cellular level, and whether the evidence suggests it is useful in real-world situations such as supporting cancer patients or maintaining health in otherwise well people.

The main compounds thought to drive reishi’s immune effects are polysaccharides, large sugar molecules that include beta-glucans, and smaller triterpenoid molecules called ganoderic acids. In test-tube and animal experiments, these substances do not simply “boost” immunity in a blanket way. Instead they act as immunomodulators, meaning they can gently dial immune activity up or down depending on the body’s needs. Polysaccharides bind to receptors on the surface of immune cells such as dectin-1, Toll-like receptors (TLR2 and TLR4), and complement receptor 3 (CR3). Once attached, they trigger internal signaling pathways including NF-κB and MAPK. These pathways switch on genes that lead to greater production of cytokines—signaling proteins such as interleukin-2 (IL-2), interferon-gamma (IFN-γ), and tumor necrosis factor-alpha (TNF-α). The result can be increased activity of macrophages (cells that engulf invaders), natural killer (NK) cells (which destroy virus-infected or cancerous cells), and T lymphocytes (key players in targeted immune responses). Triterpenoids appear to add anti-inflammatory fine-tuning in some models, helping prevent over-reaction that could lead to chronic swelling. Laboratory reviews, including work summarized by researchers in 2005 and again in more recent analyses, describe these multi-step cascades in detail, showing that the mushroom’s components can promote phagocytosis (the engulfing of threats), lymphocyte proliferation, and antibody production while also calming excessive inflammation in certain contexts.

Translating these lab findings to people requires careful clinical studies. One of the clearest pictures comes from a 2016 Cochrane systematic review led by Jin and colleagues. They examined five randomized controlled trials that together included 373 patients with various advanced cancers. When reishi extracts were given alongside standard chemotherapy or radiotherapy, patients were more likely to show a positive tumor response than those receiving only conventional treatment (relative risk 1.50). On immune measures, the review found small but statistically significant increases: CD3 cells rose by an average of 3.91 percent, CD4 cells by 3.05 percent, and CD8 cells by 2.02 percent. The CD4-to-CD8 ratio improved slightly, and overall quality of life scores (measured by the Karnofsky scale) were higher in the reishi groups. NK-cell activity showed no consistent change across the pooled data, however, and the authors noted important limitations: most studies were small, conducted in China, and carried a high risk of bias because of incomplete reporting on randomization and blinding. No clear data emerged on long-term survival.

Individual trials within that review and others add color. In a 2003 open-label study by Gao and colleagues, 34 patients with advanced-stage cancers took 1,800 mg of a reishi polysaccharide extract (Ganopoly) three times daily for 12 weeks. Eighty percent showed enhanced cellular immunity, including higher levels of IL-2, IL-6, and IFN-γ in the blood plus increased NK-cell activity. A follow-up 2005 study by the same lead researcher enrolled 36 patients with advanced lung cancer who received 5.4 grams per day of water-soluble reishi polysaccharides for 12 weeks. Results were more variable—some individuals had clear improvements in immune markers while others did not—but the authors concluded that certain subgroups of cancer patients might benefit when reishi is added to conventional care.

Evidence in healthy people is more limited but growing. In 2023, Chen and colleagues ran a randomized, double-blind, placebo-controlled trial with 157 healthy adults aged 18 to 55; 135 completed the study. Participants took 200 mg of purified reishi beta-glucan daily for 12 weeks or a matching placebo. The reishi group showed statistically significant rises in CD3+, CD4+, and CD8+ T-lymphocytes, an improved CD4-to-CD8 ratio, higher NK-cell counts, increased serum immunoglobulin A, and an 83.1 percent jump in NK-cell cytotoxicity compared with placebo. Blood safety markers stayed normal, and the supplement was well tolerated. This trial suggests reishi beta-glucan can modestly strengthen certain immune parameters even in people without disease, though the changes were not dramatic and the study lasted only three months.

Other recent work points in similar directions. A 2024 study in older women given 2,000 mg of whole reishi extract daily for eight weeks found shifts in T-cell gene expression that favored a balanced, anti-inflammatory profile without over-stimulating proliferation. Animal and cell studies continue to support the receptor-binding mechanisms described earlier, but human data remain sparse outside the cancer-support setting.

Taken together, the research indicates reishi does not act like a simple immune stimulant such as a vaccine. Its effects are subtler: it appears capable of helping restore or maintain balanced immune function, especially in people whose immunity is stressed by cancer or its treatments. In practical terms, this could mean fewer treatment-related drops in white-blood-cell activity or modestly better quality of life during therapy. For healthy individuals, any benefit seems modest and may be most noticeable in supporting everyday resilience rather than preventing specific illnesses. Importantly, no high-quality evidence shows reishi prevents cancer or infections on its own, nor does it replace standard medical care.

Safety data from the trials are reassuring for short-term use. Mild side effects such as dry mouth, mild stomach upset, or occasional nausea have been reported by a small percentage of users, but serious toxicity is rare. Because reishi can mildly thin the blood, people on anticoagulants or preparing for surgery should check with a doctor. Long-term studies beyond a year are still lacking, so ongoing medical supervision is wise.

Reishi mushroom therefore occupies an interesting middle ground. Decades of laboratory work have mapped clear mechanisms—receptor activation, cytokine signaling, and cell-function enhancement—while a handful of human trials, especially the 2016 Cochrane analysis of 373 cancer patients and the 2023 healthy-volunteer study of 135 adults, give concrete numbers showing small but measurable immune improvements. These findings suggest reishi extracts may be a useful supportive option for people undergoing cancer treatment or seeking gentle immune support, but they do not justify viewing the mushroom as a cure-all or preventive powerhouse. Anyone considering reishi should discuss it with a qualified healthcare provider, choose standardized products from reputable sources, and remember that the strongest evidence supports its role as a complement to, not a substitute for, proven therapies. Future larger and longer trials will help clarify who benefits most and at what dose, but the current body of work already offers a reasoned basis for cautious optimism about reishi’s place in immune health.

(Source : Grok)

Astragalus (Astragalus membranaceous) is a highly regarded herb belonging to the plant family Fabaceae and has a rich tradition of use within both Western herbalism and traditional Chinese medicine (TCM). Astragalus is best known as an immune modulator and Yin tonic. Astragalus has been studied for use in a variety of conditions, including asthma and allergy, kidney disease, cancer, diabetes, and heart disease. Clinically, astragalus is often utilized as an immune modulator in the prevention of upper respiratory tract infections during the winter months.

Activity

Astragalus contains a variety of constituents including flavonoids, saponins, and polysaccharides.

 Astragalus extract and its constituent astragalosides have been shown to exert antioxidant and anti-inflammatory properties, protecting brain tissue from damage, protecting mitochondria in various tissues including kidneys, and suppressing proinflammatory cytokine signaling, including in the lungs (NF-κB).
With respect to immune function, astragalus has been shown to increase subsets of immune cells in healthy patients, including neutrophils, lymphocytes, and monocytes, and has been shown to increase T- and B-cell proliferation.

In TCM, astraglus is considered a tonic for the spleen and lung meridians. Astragalus also strengthens Qi or vital energy, treats stagnant blood flow, and “improves Yin deficiency by promoting diuresis to remove edema due to inadequate transformation of dampness and Qi.”

In modern scientific research, astragalus has been studied for a range of conditions affecting the respiratory system, kidneys, heart, and the immune system. For instance, studies have shown that supplementation with astragalus can be helpful for asthma, allergy, lung cancer, chronic kidney disease, diabetes, heart failure, and fatigue. In China, astragalus is used as an injectable preparation as well as in an extract for oral use.

Allergy and Asthma

Astragalus has been shown to modify immune function in allergy and asthma. In a study of 90 children with asthma in remission, astragalus was compared to inhaled corticosteroids for preventing new asthma flares. Results showed that the effectiveness rates in preventing asthma recurrence were similar for astragalus (66%) and corticosteroids (73%, p > 0.05); however, interestingly, children receiving combined treatment had significantly higher effectiveness than either treatment alone, at 96% (p < 0.05). In a randomized, double-blind trial of 48 adult patients with a moderate to severe seasonal allergic rhinitis, use of astragalus for six weeks significantly reduced rhinitis compared to placebo.

Kidney Disease

A multicentre prospective trial of 32 patients with stage 3 or 4 chronic kidney disease evaluated the effects of a herbal formula containing astragalus and Angelica sinensis. Herbal treatment was associated with improved kidney function in 78% of patients. Serum creatinine decreased 12%, eGFR increased 21%, and albumin increased 2.7% compared to baseline.

Cancer

Astragalus has been studied in patients undergoing treatment for lung cancer and colorectal cancer and has been shown to improve appetite, immune parameters, survival measures, and tumour response as well as side effects from chemotherapy including neutropenia (immune suppression), nausea and vomiting, and neuropathy. A systematic review and meta analysis of 65 RCTs including 4,751 patients with non–small-cell lung cancer (NSCLC) found that astragalus given alongside platinum-based chemotherapy in comparison with chemo alone evaluated cancer treatment outcomes. A meta-analysis of 20 of these trials (n = 1,520) found a 35% reduced risk of death at 12 months associated with astragalus treatment.

Another meta-analysis of 57 trials showed a 35% increased rate of having a tumour response to chemotherapy associated with astragalus treatment.

A meta-analysis of 13 randomized controlled trials evaluated TCM herbs (most commonly astragalus) in combination with FOLFOX4 chemotherapy in patients with advanced colorectal cancer. The most frequently used herbs were Astragalus membranaceus, Panax ginseng, Atractylodes, Poria, Coix lachryma-jobi, and Sophora flavescens. Researchers found that the addition of herbal medicines improved tumour response rate by 25%, one-year survival by 51%, and quality of life. Treatment with herbal medicine also lowered side effects from chemotherapy including neutropenia, nausea and vomiting, and neuropathy, compared to FOLFOX4 alone.

Diabetes

In patients with type 2 diabetes, astragalus has been shown to prevent diabetic kidney damage, and it has been shown in a meta-analysis to improve glycemic control. A meta-analysis of 13 studies including 1,054 participants with type 2 diabetes investigated the effect of astragalus supplementation. Astragalus supplementation reduced fasting glucose (0.83 points) and postprandial glucose, fasting insulin, HOMA-⁠IR (insulin resistance), and hemoglobin A1C (1.7 points) compared to the control group.

Heart Disease

In a randomized trial, 90 patients with congestive heart failure (CHF) were randomized to treatment with an ACE inhibitor (perindopril) medication plus high-, moderate-, or low-dose astragalus. High dose was equivalent to 7.5 g, moderate was equivalent to 4.5 g, and low dose was equivalent to 2.25 g twice daily for 30 days. Results demonstrated a dose-dependent improvement in left ventricular ejection fraction (LVEF), a measure of the heart’s pumping ability, and patients’ walking distance. LVEF improved 59% in the high-dose group.

These data demonstrate the extent to which astragalus have been scientifically investigated in both Chinese studies as well as Western studies. Astragalus demonstrates a high safety profile as it has been well tolerated in combination with a variety of potent medications including chemotherapy and cardiovascular medications. Astragalus has demonstrated effectiveness in a range of conditions including allergy and asthma, kidney disease, diabetes, heart disease, and cancer.

Individuals taking medications should consult with a licensed health-care provider to assess whether supplementation with astragalus is appropriate.

(Source : NewRootsHerbal)

Ashwagandha (Withania somnifera) influences the immune system through several complementary actions that researchers have documented mainly in cells and animals, with growing but still limited clinical data in humans. At a molecular level, bioactive compounds in the plant — especially a group called withanolides (for example withaferin A) and related steroidal lactones — interfere with inflammatory signalling pathways such as NF-κB and MAPK. By damping those pathways, ashwagandha reduces production of pro-inflammatory cytokines (for example TNF-α, IL-6 and IL-1β) and reactive oxygen species, which helps limit excessive inflammation in injured or stressed tissues. (PMC)

At the level of innate immunity, multiple preclinical studies report that extracts of ashwagandha can increase the activity of natural killer (NK) cells, enhance macrophage phagocytosis, and support chemotaxis — all actions that improve the body’s first-line defenses against infected or abnormal cells. These effects appear to be dose- and extract-dependent and are attributed to both direct effects of withanolides on immune cells and indirect effects via reduced oxidative stress. (PMC)

For adaptive immunity, the herb has been shown to modulate T-cell responses: several studies report a tendency to shift immune balance toward a Th1-type response (with higher interferon-γ and IL-2) and to normalize overactive Th2 responses (which drive allergy and some chronic inflammations). This “rebalancing” can also include altered B-cell activity and antibody production in experimental models, which is why researchers have tested ashwagandha as a potential vaccine adjuvant. However, human clinical evidence for improved vaccine responses or broad adaptive-immune enhancement is still preliminary. (ScienceDirect)

Putting those findings together, the practical picture is that ashwagandha acts both to restrain harmful, excessive inflammation and to support cellular immune functions that clear pathogens or abnormal cells. This combined profile — anti-inflammatory plus immune-supportive — is why the herb is described as “immunomodulatory” rather than simply an immune stimulant. That distinction matters clinically: a true immunomodulator can reduce damaging inflammation in some contexts while preserving or even enhancing protective immune responses in others. (MDPI)

Finally, it’s important to be cautious about translating laboratory findings directly into clinical recommendations. Most mechanistic and efficacy data come from in vitro or animal studies and from small human trials with variable extracts and doses; high-quality, large randomized controlled trials are still needed to establish effective regimens, clear indications, and safety in people with immune disorders or those taking immunomodulatory drugs. If you’re considering ashwagandha for immune-related reasons, discuss it with a clinician, especially when you have a chronic illness or take prescription medicines. (PMC)

(Source : ChatGPT)

Laboratory and animal studies show neuroprotective actions for ashwagandha (Withania somnifera), and a handful of small human trials report modest cognitive benefits, but the clinical evidence is still preliminary and larger, longer studies are needed.

Researchers have studied ashwagandha for brain protection in two broad ways: first, by testing purified compounds from the plant (notably the withanolides such as withaferin A and related molecules) and second, by testing whole-root extracts in cells, animals and small human trials. In cell and animal experiments these compounds reduce oxidative stress and inflammation in brain tissue, help neurons resist toxic insults, and encourage processes that support neuron health such as neurite outgrowth and synaptic function. For example, several laboratory studies show that ashwagandha extracts can blunt the damage caused by beta-amyloid (a protein linked to Alzheimer’s disease), reduce markers of inflammation and cell death, and improve memory-related behavior in rodent models. These mechanistic and animal findings are summarized in recent reviews of the literature. (American Chemical Society)

How does it do that? The proposed mechanisms are familiar ones for a botanical with neuroprotective activity: antioxidant effects that lower harmful free radicals; anti-inflammatory actions that reduce damaging immune signaling in the brain; modulation of stress pathways (for example reducing excessive glucocorticoid/HPA-axis activation) that otherwise hurt neurons over time; and direct effects on protein handling and neuronal structure that can reduce toxic protein aggregation and support synapse formation. Specific chemicals from the plant — withanolides and sitoindosides — have been shown in lab work to engage these pathways, although which compound (or combination) matters for which effect is still being mapped out. (American Chemical Society)

What about human evidence? A handful of randomized, placebo-controlled trials have tested standardized root extracts in people. Some studies in stressed adults and in people with mild cognitive impairment report improved memory, attention and processing speed after several weeks to a few months of supplementation, and these trials generally reported good tolerability. However, the trials are small, used different extract preparations and doses, and often measured subjective or short-term endpoints — so while the results are encouraging, they do not yet prove that ashwagandha prevents or reverses major neurodegenerative diseases in people. Larger, longer and better-standardized clinical trials are underway or have been registered. (PubMed)

In plain terms: think of ashwagandha as a botanical that contains molecules able to protect nerve cells in laboratory settings and to nudge human cognition modestly in some small trials. That biological plausibility (antioxidant, anti-inflammatory, anti-amyloid and neurotrophic effects) makes it a promising candidate for further study, but the current human evidence is not yet strong enough to treat it as a proven therapy for Alzheimer’s, Parkinson’s or other major brain diseases. If you’re considering it for memory or brain health, it’s sensible to discuss it with a clinician — especially because product quality, dose and interactions vary. (PMC)

(Source : ChatGPT) (Image : Grok)

Prompt :  Here (x) you said that Ashwagandha had anticancer properties, but in this article it says it doesn't (x) according to Memorial Sloan Kettering Cancer Center Integrative Medicine Service Pharmacist Jason Hou. If it have anticancer properties please write a plain language text (not a bullet point list) explaining the science behind it.

A :  Short answer first: Memorial Sloan Kettering is correct that there’s no strong clinical evidence yet that ashwagandha cures or prevents cancer in people — most of the anti-cancer data come from cells and animals. That said, scientists have identified multiple plausible biochemical ways that ashwagandha’s chemicals (especially a molecule called withaferin A) can damage cancer cells or make tumors more vulnerable to treatment in laboratory models. (Memorial Sloan Kettering Cancer Center)

Here’s a plain-language explanation of the science behind those anticancer effects.

At the chemical level, the most studied ingredient is withaferin A, one of many “withanolides” in Withania somnifera. In test-tube and animal experiments withaferin A looks like a multitool against cancer: it can directly damage cancer cells, block signals that help tumors survive and spread, and make standard drugs or radiation work better. Reviews that summarize hundreds of lab studies describe withaferin A as “pleiotropic” — meaning it hits many different molecular targets rather than only one. (PMC)

One major way it acts is by pushing cancer cells into programmed cell death (apoptosis). Withaferin A raises reactive oxygen species (ROS) inside tumor cells and triggers enzymes called caspases that execute cell death. In other experiments it interferes with proteins that normally keep damaged cells alive, so cancer cells are more likely to self-destruct. Those pathways have been observed across many cancer cell types in the lab. (Frontiers)

Another common effect is blocking growth and invasion signals. Withaferin A and some whole-plant extracts suppress pro-growth routes that cancers use (for example NF-κB and STAT3 signaling, and PI3K/Akt pathways). By interfering with these signals the compounds slow cell division, reduce inflammation that feeds tumors, and lower production of factors (like VEGF) that tumors use to build new blood vessels. That helps starve a tumor and limits its ability to grow and spread in animal models. (MDPI)

Withaferin A also affects the cytoskeleton and proteins that enable metastasis. It binds to structural proteins such as vimentin and disrupts the cell’s scaffolding, which can reduce cancer cell motility and invasion in laboratory assays. Several studies report reduced metastasis in mice treated with withaferin A. (PMC)

Finally, there are immune and treatment-sensitizing effects: some studies show ashwagandha extracts can stimulate parts of the immune system (natural killer cells, macrophages) and make tumor cells more sensitive to chemotherapy or radiation — either by weakening tumor defenses or by reversing mechanisms of drug resistance. That’s why researchers are exploring combination approaches in preclinical models and a few early clinical protocols. (dovepress.com)

Why MSK says “no”: the lab and animal results are promising, but they do not automatically mean the herb will treat human cancer safely or effectively. Most anticancer effects require concentrations that are easy to reach in a petri dish but hard to produce in a human without side effects. Human clinical trials that test whether ashwagandha (or isolated withaferin A) actually improves cancer outcomes are very limited; what exists so far mostly looks at symptom relief (fatigue, cognitive problems) or small pilot combinations, not proof of tumor-shrinking efficacy. Until well-designed large clinical trials exist, major cancer centers rightly advise caution. (Memorial Sloan Kettering Cancer Center)

Practical takeaway: the science supports strong preclinical anticancer activity and multiple believable mechanisms (pro-apoptosis, anti-growth signaling, anti-angiogenesis, anti-metastasis, immune modulation, and chemo/radio sensitization) — but clinical proof is lacking and supplements vary widely in strength and purity. If you or someone with cancer is considering ashwagandha, discuss it with the oncology team first because it can interact with treatments and has dose / safety questions that remain unresolved. (PMC)

Ashwagandha Leaf Extract: What a 2007 Study Discovered :

The 2007 study by Widodo and colleagues tested whether a leaf extract of ashwagandha (they called the active preparation “i-Extract”) could inhibit cancer. Using lab-grown human cells and tumour-formation tests in nude mice, the team found that the leaf extract impaired the growth of a range of cancer cells while having much less effect on normal cells. Through chemical fractionation they isolated a single active component—withanone—which showed the strongest tumour-inhibiting activity. Mechanistic experiments using gene-silencing showed that the extract’s killing effect depended on the tumour-suppressor protein p53: in cancer cells the extract activated p53, which in turn caused either cell-cycle arrest or programmed cell death (apoptosis). In short, the paper reported selective anti-tumour activity in cells and reduced tumour formation in mice, and it identified withanone as a promising active molecule that appears to work at least in part by activating p53. (PubMed)

It’s important to stress what the authors themselves said: these are preclinical findings (cell and animal work). They point to a biologically plausible anticancer action and a candidate compound, but they do not demonstrate safety or effectiveness in humans—clinical trials would be required to assess that. Later laboratory work from the same group and others explored additional mechanisms (for example, induction of reactive-oxygen-species signalling) that may contribute to the selective killing seen with the extract. (PMC)

(Source : ChatGPT)

Oolong tea does appear to have healthful properties, although the strength of the evidence varies by outcome and much of the best mechanistic work comes from lab or animal studies rather than large, definitive human trials. At the chemical level, oolong is made from the same plant as green and black tea (Camellia sinensis) but is partially oxidized, which gives it a mix of polyphenols, catechins and theaflavins. These compounds act as antioxidants and mild anti-inflammatory agents; they can neutralize free radicals and influence metabolic and cellular pathways in ways that plausibly protect tissues from damage. Laboratory analyses and reviews of oolong’s phytochemistry describe this rich polyphenol profile and the tea’s measurable antioxidant activity. (PMC)

Because of those antioxidant and bioactive compounds, observational studies and some clinical research link regular tea drinking — including oolong — with lower risk markers for heart disease. People who drink moderate amounts of tea have been found, in population studies, to have lower rates of death from cardiovascular causes and better blood-lipid profiles; smaller trial data and animal work also hint that tea polyphenols can improve vascular function and reduce cholesterol and triglycerides. These associations don’t prove causation (tea drinkers may differ from non-drinkers in other healthy behaviors), but the pattern of observational findings plus plausible mechanisms makes a cardiovascular benefit one of the more consistent and credible claims. (The Nutrition Source)

Oolong is often discussed for its effects on weight and metabolism. Some trials and animal studies report modest decreases in body fat and improvements in markers of lipid metabolism after regular oolong consumption or supplementation with oolong extracts; caffeine plus certain tea polyphenols can slightly increase energy expenditure and fat oxidation, which may help with weight control when combined with diet and exercise. The human studies are usually small and short, so any weight effects should be seen as potentially helpful but not dramatic or guaranteed. (PubMed)

The picture is mixed for blood sugar and diabetes. Several large observational studies and meta-analyses find that regular tea drinking (especially when averaged across tea types) is associated with a lower risk of type 2 diabetes, but studies focused specifically on oolong have produced inconsistent results — a few reported no benefit and at least one older study even reported a higher diabetes risk in a subgroup of heavy oolong drinkers, though that finding has not been universally replicated and may reflect confounding or regional differences in preparation and lifestyle. Overall, tea may help glucose metabolism for some people, but the evidence for oolong specifically is variable and more research is needed. (PMC)

Beyond those areas, animal and lab studies suggest oolong polyphenols might support cognitive function, influence the gut microbiome, and show anti-cancer or bone-protective effects in early experiments, but human data are preliminary. There are also practical cautions: oolong contains caffeine (less than coffee but enough to matter for sensitive people), tea can reduce absorption of non-heme iron when consumed with iron-rich plant foods, and very large amounts of any tea can add fluoride or interact with medications. For most people, moderate oolong intake (a few cups a day) is a low-calorie, antioxidant-rich choice that can be part of a healthy diet, while pregnant people, those with iron-deficiency, or people sensitive to caffeine should moderate intake and consult their clinician if unsure. (ScienceDirect)

In short, oolong tea brings antioxidant and polyphenol-driven effects that plausibly support heart and metabolic health and may modestly aid weight control; many findings are promising but not definitive, so think of oolong as a healthy beverage choice rather than a cure-all.

(Source : ChatGPT)

Quinton’s Water (often called “marine plasma” or “Quinton marine plasma”) is purified seawater processed and bottled for oral use; it’s rich in naturally occurring major minerals (like sodium, magnesium, calcium) and many trace elements in roughly the proportions found in ocean water. Advocates say that because its mineral profile is broad and present in ionic form, small amounts can help re-establish electrolyte and fluid balance, support cellular hydration, and supply trace nutrients that are otherwise missing in a modern diet. (Quinton Medical)

A common practical claim is that Quinton’s Water can speed recovery after exercise, help with rehydration, and reduce fatigue because of its electrolytes (especially magnesium) and simple bioavailability. Some research on deep-sea water and isotonic seawater suggests potential benefits for physical performance, recovery and aspects of metabolism, so there is a limited scientific basis for the idea that certain types of seawater preparations can support hydration and athletic recovery. However, most of the stronger claims about “restoring all cellular function” go beyond what the clinical literature currently proves. (PMC)

Proponents also point to immunomodulatory and skin-healing effects: small laboratory and product-sponsored reports describe changes in immune cell activity and improvements in skin condition when isotonic seawater is applied topically or used in specific protocols. These findings are intriguing but tend to be preliminary, and many of the positive statements you’ll read come from manufacturer literature rather than large, independent randomized trials. If you’re weighing these as therapeutic claims, it’s fair to treat them as promising but not definitively proven. (Quinton Medical)

On safety and regulation: bottled seawater products vary in concentration (isotonic vs. hypertonic) and sodium content, so people with high blood pressure, kidney disease, or salt-sensitive conditions should be cautious and consult a clinician before use. There is also precedent for contaminated unregulated ocean-water supplements in the past, which led to official warnings, so it’s important to choose reputable, tested brands and to treat any strong medical claims with skepticism. Finally, many product pages include disclaimers that their statements have not been evaluated by regulatory agencies and that products are marketed as supplements rather than medicines. (Gouvernement du Canada)

In short, Quinton’s Water is a mineral-rich seawater supplement that plausibly helps with electrolyte balance, hydration and potentially recovery in some contexts; it has some supportive laboratory and small-scale evidence but not a large body of definitive clinical trials for the broader therapeutic claims. 

Here is a concise summary of what published studies — including small, pilot and product-sponsored studies — have actually found about health effects attributed to Quinton’s Water / marine plasma and related seawater preparations.

Clinical and randomized trials of nasal and upper-respiratory uses consistently show the clearest and most reproducible benefits. Trials and reviews of isotonic and hypertonic seawater or sea-salt saline used as nasal sprays, nasal irrigation or gargles report faster symptom resolution in acute rhinitis, reduced recurrence of rhinitis in children, improved subjective nasal comfort in athletes during intense training, and shorter duration or reduced severity of some viral upper respiratory infections when used early (several randomized or controlled pilot trials and systematic reviews). These effects are the most solidly supported and are generally attributed to mechanical cleansing, improved mucociliary function and local changes in the nasal environment rather than to systemic “remineralization.” (JAMA Network)

A separate body of small clinical work has examined “deep-sea water” or magnesium-rich seawater extracts taken orally and reported metabolic benefits in limited settings. Several randomized or controlled pilot studies and reviews have found that consumption of magnesium-enriched deep-sea water can improve measures of insulin sensitivity in people with pre-diabetes or metabolic disturbances, and some trials reported reductions in total cholesterol and LDL cholesterol after weeks of drinking deep-sea water preparations. These studies are promising for metabolic endpoints (glycemic control and lipid profile) but tend to be small, sometimes short in duration, and often use specific, high-magnesium preparations rather than the diluted isotonic products commonly sold as Quinton’s Water. (PMC)

At the cellular and laboratory level there are mixed findings. In vitro experiments with Quinton isotonic and hypertonic preparations have demonstrated measurable effects on human peripheral blood mononuclear cells (changes in viability, morphology and some proliferation parameters), which supports the idea that marine plasma can alter cell behavior under experimental conditions. Other small lab or pilot cell-culture studies looking for anti-aging or “reconstructive” effects have been inconclusive or failed to reproduce dramatic benefits, showing that laboratory findings do not yet translate into consistent evidence for broad systemic anti-aging claims. (PubMed)

There are also several smaller or device-based studies showing symptomatic improvements when seawater-derived or sea-salt physiological saline sprays are used for nasal congestion, sleep-related breathing complaints and related symptoms in adults; these tend to be pragmatic studies (product or device evaluations) rather than large independent trials, and results are modest but reproducible for symptom relief. Hypertonic saline irrigation and gargling trials have shown reductions in symptom duration for some viral upper respiratory tract infections in pilot randomized work. (PMC)

Across all topics the pattern is the same: small trials, pilot studies and some mechanistic lab work point to real, plausible benefits for (1) local nasal/upper-airway symptom relief and shortened URTI symptoms with topical/isotonic or hypertonic seawater, and (2) possible metabolic effects from magnesium-rich deep-sea water on insulin sensitivity and lipids. However, the evidence is not yet large or uniform enough to support many broader systemic therapeutic claims often made in marketing materials. Many studies use different preparations (isotonic vs hypertonic vs concentrated deep-sea extracts), vary in dose and duration, and in some cases are industry-sponsored, so generalizing results to all “Quinton” products is not justified without attention to the specific formulation used in each study. (MDPI)

► Read More : Osmosis and tonicity. Hypertonic, isotonic, and hypotonic solutions and their effect on cells.

(Source : ChatGPT 1 & 2)

The 90.10-CUBE is a commercial “quantum energy” product sold by a company called 90.10 that markets the device as a “quantum processor” which can generate a harmonizing “quantum energy” field, store that energy in objects, and even “entangle” virtual beds or other targets with the cube so they can be affected at a distance. The manufacturer’s website and support pages describe physical modules that are “treated” by a proprietary process and claim the cube can “burn” energy and frequencies into objects, create a torus field around the cube, and use a so-called “quantum language” to teleport energy and frequencies into matter. Those claims and marketing descriptions come directly from the company. (9010.com, medbed2.helpscoutdocs.com)

A few small laboratory papers and reports (authors connected with proponents or the company) claim biological effects—examples include in-vitro studies reporting faster fibroblast wound closure or changes in cultured intestinal cells when a cube was located many thousands of kilometers away. Those reports describe experiments that the authors interpret as effects of the 90.10 “quantum entanglement” process, but they are published outside mainstream, high-impact journals and have not been independently replicated by unrelated laboratories. In short, there exist only a few proponent-authored papers claiming positive lab findings; independent confirmation is absent. (Biomedres, appliedcellbiology.com)

On the physics side, the claims of the cube—especially the idea that quantum entanglement or a “quantum language” can be used to teleport usable energy or information instantly to macroscopic biological targets—conflict with well-established principles of quantum theory. The no-communication (no-signaling) theorem and related results show that entanglement produces correlations but cannot be used to send controllable information or energy faster than light; moreover, entanglement is fragile and is destroyed (decoheres) extremely quickly in warm, wet, noisy systems like biological tissue. For these reasons, mainstream physics gives no known mechanism that could make the manufacturer’s claims physically plausible. (Wikipédia, Physical Review)

Putting those threads together: the 90.10-CUBE is a marketed wellness device with proprietary, poorly-defined concepts (“quantum energy”, “quantum language”) and a small number of supportive reports from proponents. There is no credible, independently replicated scientific evidence that it can transmit healing effects at a distance by quantum entanglement, and its basic mechanism as described contradicts fundamental results in quantum physics. The only effects that are plausibly expected at present are placebo or expectation effects in users; relying on the cube instead of proven medical care could be risky. (9010.com, Biomedres, Wikipédia)

(...)  The 90.10-CUBE is a commercial “quantum energy” product sold by a company called 90.10 that markets the device as a “quantum processor” which can generate a harmonizing “quantum energy” field, store that energy in objects, and even “entangle” virtual beds or other targets with the cube so they can be affected at a distance. The manufacturer’s website and support pages describe physical modules that are “treated” by a proprietary process and claim the cube can “burn” energy and frequencies into objects, create a torus field around the cube, and use a so-called “quantum language” to teleport energy and frequencies into matter. Those claims and marketing descriptions come directly from the company. (9010.com, medbed2.helpscoutdocs.com)

A few small laboratory papers and reports (authors connected with proponents or the company) claim biological effects—examples include in-vitro studies reporting faster fibroblast wound closure or changes in cultured intestinal cells when a cube was located many thousands of kilometers away. Those reports describe experiments that the authors interpret as effects of the 90.10 “quantum entanglement” process, but they are published outside mainstream, high-impact journals and have not been independently replicated by unrelated laboratories. In short, there exist only a few proponent-authored papers claiming positive lab findings; independent confirmation is absent. (Biomedres, appliedcellbiology.com)

On the physics side, the claims of the cube—especially the idea that quantum entanglement or a “quantum language” can be used to teleport usable energy or information instantly to macroscopic biological targets—conflict with well-established principles of quantum theory. The no-communication (no-signaling) theorem and related results show that entanglement produces correlations but cannot be used to send controllable information or energy faster than light; moreover, entanglement is fragile and is destroyed (decoheres) extremely quickly in warm, wet, noisy systems like biological tissue. For these reasons, mainstream physics gives no known mechanism that could make the manufacturer’s claims physically plausible. (Wikipédia, Physical Review)

Putting those threads together: the 90.10-CUBE is a marketed wellness device with proprietary, poorly-defined concepts (“quantum energy”, “quantum language”) and a small number of supportive reports from proponents. There is no credible, independently replicated scientific evidence that it can transmit healing effects at a distance by quantum entanglement, and its basic mechanism as described contradicts fundamental results in quantum physics. The only effects that are plausibly expected at present are placebo or expectation effects in users; relying on the cube instead of proven medical care could be risky. (9010.com, Biomedres, Wikipédia)

(...)  In real physics the word “quantum” attaches to specific, measurable behaviors of tiny systems: electrons in atoms, photons (light particles), superconducting circuits, etc. One very important quantum idea is quantization — energy comes in discrete packets. Think of an atom like a staircase: an electron can stand on one step or another, but not in between. When it jumps between steps it absorbs or emits a photon — a real packet of electromagnetic energy you can measure. That’s what physicists mean when they talk about quantum energy in an experiment: precise, measurable amounts of energy tied to microscopic systems.

(...) ➔ About  _Fibroblast wound healing:_ One in vitro study (Dartsch 2021) exposed human fibroblast cultures to a device claiming “90.10 quantum entanglement” from 8,600 km away. The authors reported **faster wound closure** (greater cell migration/proliferation) in treated dishes than controls.

In vitro (Lab) Experiments

• Fibroblast wound healing: One in vitro study (Dartsch 2021) exposed human fibroblast cultures to a device claiming “90.10 quantum entanglement” from 8,600 km away. The authors reported faster wound closure (greater cell migration/proliferation) in treated dishes than controls (biomedres.us). However, this work appeared in a little-known open-access journal and has not been independently replicated. Importantly, mainstream physics offers no plausible explanation for such a “quantum entanglement” effect on cells, and this study is not evidence of a clinically useful therapy without further validation.

(...) The genuinely new-physics explanation would claim there exists a previously unknown mechanism that can transmit biologically relevant information or influence nonlocally and robustly across distance and through thermal environments. For such an explanation to be scientific it must be specific and testable: it would have to tell us what the carrier of the effect is (a new field? a modification of quantum correlations that survives decoherence at body temperature?), how it couples to biomolecules or cells, how it carries information (is it frequency coded? state-coded?), and what symmetries or conservation laws it obeys or breaks. If true, this would imply measurable, reproducible signatures that differ from ordinary artifacts: the effect would persist inside good EM shielding and vibration isolation, be independent of air exchange, show a clear dependence on experimental variables predicted by the new theory (for example a precise frequency dependence or functional form with distance), and—most dramatically—would allow controlled transfer of information in a way that standard quantum mechanics forbids. That last point matters because standard quantum theory (the no-signaling theorem) prevents using entanglement to send controllable signals; so an observed ability to send encoded information would falsify a pillar of present physics.

Hardware :

The 90.10-CUBE is physically built as a two-level acrylic rack (the visible “holder”) that accepts twelve discrete metal modules; six modules sit on the upper level and six on the lower level. Each module is an aluminum element that the company says has been treated by a proprietary process; the manufacturer’s description emphasizes that the modules are deliberately arranged and fixed in place (some held with small magnets) so the assembly has a defined “positive” pole at the top and a “negative” pole at the bottom and an energy field between them. (90.10, Biologie Cellulaire Appliquée)

The vendor describes the modules in marketing terms (a per-module output of “16 QEPPs,” multiplied across the twelve modules to produce a larger claimed field), and the cube is presented as a passive structure rather than an ordinary electronic instrument. The company also markets associated software and services (for example a “quantum processor” / MedBed OS and remote “entanglement” procedures) that are part of the product ecosystem, but those are separate from the simple hardware rack and module assembly. (90.10, ResearchGate)

What you will not find in the publicly available materials are conventional electronics schematics, power-supply specifications, or engineering data showing sensors, transmitters, or measurable output signals the way a normal electronic or RF device would provide. The internal “treatment” of the aluminum modules and the physical mechanism claimed by the company are proprietary and described in non-standard terms (e.g., “quantum energy,” “quantum entanglement”); independent engineering disclosures or peer-reviewed technical analyses of the cube’s electronics or measurable emissions are not provided by the vendor. That means the visible, verifiable parts are essentially the acrylic holder, the twelve aluminum modules, and the magnets/fixtures that hold them, while the rest of the device’s purported function is described in marketing and proponent papers rather than in conventional technical documentation. (90.10, Biologie Cellulaire Appliquée, Biomedres)

(Source : ChatGPT)